KR20190135902A - Fermented product of garlic and Cirsium setidens nakai by lactic acid bacteria, method of manufacturing the same, and use of the same - Google Patents
Fermented product of garlic and Cirsium setidens nakai by lactic acid bacteria, method of manufacturing the same, and use of the same Download PDFInfo
- Publication number
- KR20190135902A KR20190135902A KR1020180126805A KR20180126805A KR20190135902A KR 20190135902 A KR20190135902 A KR 20190135902A KR 1020180126805 A KR1020180126805 A KR 1020180126805A KR 20180126805 A KR20180126805 A KR 20180126805A KR 20190135902 A KR20190135902 A KR 20190135902A
- Authority
- KR
- South Korea
- Prior art keywords
- garlic
- gondre
- lactobacillus
- extract
- lactic acid
- Prior art date
Links
- 235000004611 garlic Nutrition 0.000 title claims abstract description 111
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title claims abstract description 98
- 239000004310 lactic acid Substances 0.000 title claims abstract description 49
- 235000014655 lactic acid Nutrition 0.000 title claims abstract description 49
- 241000894006 Bacteria Species 0.000 title claims abstract description 46
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 241001356908 Cirsium setidens Species 0.000 title abstract description 4
- 244000245420 ail Species 0.000 title 1
- 240000002234 Allium sativum Species 0.000 claims abstract description 111
- 239000000203 mixture Substances 0.000 claims abstract description 66
- 102000004190 Enzymes Human genes 0.000 claims abstract description 42
- 108090000790 Enzymes Proteins 0.000 claims abstract description 42
- 239000000284 extract Substances 0.000 claims abstract description 40
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 36
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 26
- 239000006000 Garlic extract Substances 0.000 claims abstract description 20
- 235000020706 garlic extract Nutrition 0.000 claims abstract description 20
- 235000013361 beverage Nutrition 0.000 claims abstract description 13
- 238000000855 fermentation Methods 0.000 claims description 53
- 230000004151 fermentation Effects 0.000 claims description 53
- 239000000047 product Substances 0.000 claims description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 241000186660 Lactobacillus Species 0.000 claims description 19
- 229940039696 lactobacillus Drugs 0.000 claims description 19
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 6
- 244000199866 Lactobacillus casei Species 0.000 claims description 6
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 6
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 6
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 6
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 6
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims description 6
- 230000006872 improvement Effects 0.000 claims description 6
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 6
- 229940017800 lactobacillus casei Drugs 0.000 claims description 6
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 5
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 5
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 4
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 4
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 241000186012 Bifidobacterium breve Species 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 claims 3
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims 3
- 238000007654 immersion Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 11
- 235000013376 functional food Nutrition 0.000 abstract description 8
- 239000000463 material Substances 0.000 abstract description 3
- 229940088598 enzyme Drugs 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 24
- 235000006708 antioxidants Nutrition 0.000 description 22
- 239000002994 raw material Substances 0.000 description 17
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
- 235000008504 concentrate Nutrition 0.000 description 16
- 239000012141 concentrate Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 230000003013 cytotoxicity Effects 0.000 description 11
- 231100000135 cytotoxicity Toxicity 0.000 description 11
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical class [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 238000002376 fluorescence recovery after photobleaching Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000008213 purified water Substances 0.000 description 11
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- -1 carotenoids Chemical class 0.000 description 9
- 229930003935 flavonoid Natural products 0.000 description 9
- 235000017173 flavonoids Nutrition 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 230000005965 immune activity Effects 0.000 description 8
- 230000001953 sensory effect Effects 0.000 description 8
- 229960005070 ascorbic acid Drugs 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 150000002215 flavonoids Chemical class 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 239000002211 L-ascorbic acid Substances 0.000 description 6
- 235000000069 L-ascorbic acid Nutrition 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 6
- 206010013911 Dysgeusia Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 235000019985 fermented beverage Nutrition 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000013824 polyphenols Nutrition 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 150000002989 phenols Chemical class 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 230000006433 tumor necrosis factor production Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 2
- 235000011430 Malus pumila Nutrition 0.000 description 2
- 235000015103 Malus silvestris Nutrition 0.000 description 2
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 235000014443 Pyrus communis Nutrition 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 244000126002 Ziziphus vulgaris Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000001493 benign recurrent intrahepatic cholestasis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000019189 interleukin-1 beta production Effects 0.000 description 2
- 230000031261 interleukin-10 production Effects 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 229960004592 isopropanol Drugs 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 235000019659 mouth feeling Nutrition 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 241001432959 Chernes Species 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- WVVOBOZHTQJXPB-UHFFFAOYSA-N N-anilino-N-nitronitramide Chemical compound [N+](=O)([O-])N(NC1=CC=CC=C1)[N+](=O)[O-] WVVOBOZHTQJXPB-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- DUXQKCCELUKXOE-UHFFFAOYSA-N Pectolinarigenin-Biosid Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C(OC)=C2OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(C)O2)O)O1 DUXQKCCELUKXOE-UHFFFAOYSA-N 0.000 description 1
- SEXCCMQJDXQBOE-UHFFFAOYSA-N Pectolinarin Natural products C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C(OC)=C2OC1C(O)C(O)C(OC2C(C(O)C(O)C(C)O2)O)C(CO)O1 SEXCCMQJDXQBOE-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- HVGMINHJTDNOLV-UHFFFAOYSA-N hispidulin-7-O-neohesperidoside Natural products C1=C2OC(C=3C=CC(O)=CC=3)=CC(=O)C2=C(O)C(OC)=C1OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HVGMINHJTDNOLV-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 238000013386 optimize process Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- DUXQKCCELUKXOE-CBBZIXHGSA-N pectolinarin Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(O)C(OC)=C2O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O1 DUXQKCCELUKXOE-CBBZIXHGSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- PVGBHEUCHKGFQP-UHFFFAOYSA-N sodium;n-[5-amino-2-(4-aminophenyl)sulfonylphenyl]sulfonylacetamide Chemical compound [Na+].CC(=O)NS(=O)(=O)C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 PVGBHEUCHKGFQP-UHFFFAOYSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/212—Garlic
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Fruits And Vegetables (AREA)
Abstract
Description
본 발명은 마늘 및 곤드레 유산균 발효물, 그의 제조방법 및 용도에 관한 것으로, 보다 상세하게는 마늘 추출물 및 곤드레 효소처리 추출물의 혼합물을 유산균으로 발효시킨 마늘 및 곤드레 유산균 발효물, 그의 제조방법 및 이를 포함하는 항산화 및 면역개선용 조성물에 관한 것이다.The present invention relates to garlic and gondry lactobacillus fermented product, a method for preparing the same, and a use thereof, and more particularly, to a garlic and gondola lactobacillus fermented product obtained by fermenting a mixture of garlic extract and gondre enzyme-treated extract with lactic acid bacteria, a method for preparing the same, and the same. It relates to a composition for antioxidant and immune improvement.
식품 첨가물, 농약, 화학비료, 의약품, 불규칙적인 식습관, 서구화된 식사 등으로 인해 면역력 감소로 인한 잦은 질병, 고혈압, 당뇨, 비만 등 성인병 환자가 계속 증가하고 있으며, 이에 따라 자연지향적인 삶이 강해짐과 동시에 건강 및 의료 정보 등 건강에 대한 관심이 계속적으로 증가하여 최근에는 기능성을 갖는 건강기능식품, 보조식품에 많은 관심이 증가하고 있다. Due to food additives, pesticides, chemical fertilizers, medicines, irregular eating habits and westernized diets, the number of adult diseases such as frequent illnesses, high blood pressure, diabetes, obesity due to reduced immunity continue to increase, resulting in a stronger natural-oriented life. Interest in health, such as health and medical information continues to increase, and in recent years, a lot of interest in functional health foods, supplements have increased.
건강 식품의 기능적 활성은 카로티노이드, 식이 섬유, 폴리 불포화 지방산, 생체활성 펩타이드 및 페놀 화합물과 같은 수많은 생체활성 화합물에서 유래된다고 알려져 있다 (Trends in Food Science & Technology, 69, 214-219 (2017); Siscovick et al., Circulation, CIR (2017)).The functional activity of health foods is known to be derived from numerous bioactive compounds such as carotenoids, dietary fiber, polyunsaturated fatty acids, bioactive peptides and phenolic compounds (Trends in Food Science & Technology, 69, 214-219 (2017); Siscovick et al., Circulation, CIR (2017)).
마늘(Allium sativum L.)은 항산화, 항암, 항노화, 항균효과와 혈행개선, 심혈관계에 좋은 효과를 주는 것을 보고되어, 2002년 미국 시사주간지 타임이 선정한 10가지 건강식품에 포함되었고, 미국 국립암연구소는 항암작용이 있는 48개 식품 중 마늘을 첫 번째로 선정할 만큼 그 효능이 탁월하다고 알려져 있다.Garlic ( Allium sativum L. ) has been reported to have antioxidant, anti-cancer, anti-aging, antimicrobial effects, blood circulation improvement, and good cardiovascular effects.It was included in the 10 health foods selected by the Times Magazine in 2002. It is known that its efficacy is excellent enough to select garlic first among 48 foods with anticancer activity.
곤드레(Cirsium setidens nakai)는 수세기 동안 전통 한의학으로 사용되어 왔는데, 국화과에 속하는 여러해 살이 풀로 주로 강원도에 분포한다. 상기 곤드레는 히스피둘린 7-O-네오헤스페리오사이드(hispidulin 7-O-neohesperidoside), 펙토리나린(pectolinarin), 루테오린(luteolin), 아피게닌(apigenin)과 같은 생리 활성 화합물을 포함하고 있기 때문에, 부종, 출혈 및 객혈 치료에 사용되었다 (Archives of pharmacal research, 34(3), 455 (2011)). Cirsium setidens nakai has been used as a traditional Chinese medicine for centuries. It is a perennial herb belonging to the Asteraceae family, distributed mainly in Gangwon-do. The gondre contains bioactive compounds such as hispidulin 7-O-neohesperidoside, pectolinarin, luteolin, and apigenin. Therefore, it has been used for the treatment of edema, bleeding and hemoptysis (Archives of pharmacal research, 34 (3), 455 (2011)).
또한, 곤드레는 항산화 활성, 간 보호 활성, 비알콜성 지방간 질환에 대한 활성이 있다고 알려져 있다 (The American journal of Chinese medicine, 36(01), 107-114 (2008); Biological and Pharmaceutical Bulletin, 31(4), 760-764 (2008); Bioscience, biotechnology, and biochemistry, 77(7), 1424-1429 (2013)).In addition, Gondre is known to have antioxidant activity, hepatoprotective activity, and activity against nonalcoholic fatty liver disease (The American journal of Chinese medicine, 36 (01), 107-114 (2008); Biological and Pharmaceutical Bulletin, 31 ( 4), 760-764 (2008); Bioscience, biotechnology, and biochemistry, 77 (7), 1424-1429 (2013)).
한편, 마늘을 활용한 종래기술로는 마늘 발효 추출물을 함유한 식품 첨가물(공개특허공보 제10-2018-0002046호), 마늘 발효 추출물을 함유한 화장품(공개특허공보 제2018-0001765호), 마늘 발효 추출물을 포함하는 면역증강용 조성물(공개특허공보 제10-2016-0060443호) 등이 개시되어 있다.Meanwhile, conventional techniques using garlic include food additives containing garlic fermented extract (Patent Publication No. 10-2018-0002046), cosmetics containing garlic fermented extract (Patent Publication No. 2018-0001765), garlic Disclosed is a composition for immunopotentiation comprising a fermentation extract (Patent Publication No. 10-2016-0060443) and the like.
또한, 곤드레를 활용한 종래기술로는 생물전환을 통한 지방세포 분화 저해용 곤드레 발효물의 제조방법(공개특허공보 제10-2017-0079448호), 곤드레 추출물을 유효성분으로 하는 혈당강화용 조성물(공개특허공보 제10-2017-0058075호), 곤드레 추출물을 이용한 뇌신경세포 보호용 빵(공개특허공보 제10-2015-0092400호) 등이 개시되어 있다.In addition, the conventional technology using the gondre as a method for producing a gondry fermentation for inhibiting adipocyte differentiation through bioconversion (Publication Patent Publication No. 10-2017-0079448), a composition for enhancing blood sugar using a gondre extract as an active ingredient Patent Publication No. 10-2017-0058075), Bread for protecting brain nerve cells using Gondre extract (Patent Publication No. 10-2015-0092400) and the like are disclosed.
그러나, 항산화 활성 및 면역 활성이 우수한 곤드레는 채취 또는 재배하여 공급할 수 있는 양이 한정되어 있기 때문에, 마늘과 곤드레의 블렌딩을 통한 새로운 항산화 및 면역 강화용 조성물의 개발이 절실히 요구되고 있는 실정이다.However, since the gondre excellent in antioxidant activity and immune activity is limited in the amount that can be collected or cultivated and supplied, development of a new antioxidant and immune enhancing composition through blending of garlic and gondre is urgently required.
본 발명은 상기와 같은 종래기술의 문제점을 해결하기 위하여 안출된 것으로서, 본 발명의 목적은 마늘 및 곤드레 유산균 발효물을 제공하는 것이다.The present invention has been made to solve the problems of the prior art as described above, it is an object of the present invention to provide a garlic and Gondre lactic acid bacteria fermentation.
본 발명의 다른 목적은 상기 마늘 및 곤드레 유산균 발효물의 제조방법을 제공하는 것이다.Another object of the present invention is to provide a method for producing the garlic and gondre lactic acid bacteria fermentation.
본 발명의 또 다른 목적은 마늘 및 곤드레 유산균 발효물을 포함함으로써, 항산화 활성 및 면역 활성이 강화된 조성물을 제공하는 것이다.Still another object of the present invention is to provide a composition having enhanced antioxidant and immune activity by including garlic and gondle lactic acid bacteria fermentation.
본 발명은 상기와 같은 목적을 달성하기 위하여, 마늘 추출물 및 곤드레 효소처리 추출물의 혼합물을 유산균으로 발효시킨, 마늘 및 곤드레 유산균 발효물을 제공한다.In order to achieve the above object, the present invention provides a garlic and gondry lactobacillus fermented product obtained by fermenting a mixture of garlic extract and gondre enzyme treatment extract with lactic acid bacteria.
또한, 본 발명은 (a) 마늘 추출물 및 곤드레 효소처리 추출물을 혼합하는 단계, 및 (b) 상기 혼합된 마늘 추출물 및 곤드레 효소처리 추출물의 혼합물에 유산균을 접종하고, 발효시키는 단계를 포함하는 마늘 및 곤드레 유산균 발효물의 제조방법을 제공한다. In addition, the present invention is a garlic comprising the step of inoculating and fermenting lactic acid bacteria in the mixture of (a) garlic extract and gondre enzyme treatment extract, and (b) the mixture of the garlic extract and gondle enzyme treatment extract; Provided is a method of preparing gondre lactic acid bacteria fermentation.
또한, 본 발명은 마늘 및 곤드레 유산균 발효물을 포함하는 항산화 및 면역개선용 조성물을 제공한다.In addition, the present invention provides a composition for antioxidant and immune improvement, including garlic and Gondre lactic acid bacteria fermentation.
본 발명에 의하면, 마늘과 곤드레의 블렌딩 및 유산균 발효를 이용하여 항산화 활성 및 면역 활성이 증진된 마늘과 곤드레 유산균 발효물을 제공할 수 있다.According to the present invention, by using a blend of garlic and gondre and fermentation of lactic acid bacteria, it is possible to provide garlic and gondry lactobacillus fermented products having enhanced antioxidant and immune activity.
또한, 본 발명에 의하면 상기의 유산균 발효물을 음료 등과 같은 건강기능 식품의 소재로 활용할 수 있는 장점이 있다.In addition, according to the present invention has the advantage that the lactic acid bacteria fermented product can be used as a material of health functional food, such as beverages.
도 1은 본 발명의 일 실시예에 따른 마늘 및 곤드레 유산균 발효물의 제조 공정도를 나타낸 것이다.
도 2는 본 발명의 일 실시예에 따른 곤드레 효소처리 추출물의 제조 공정도를 나타낸 것이다.
도 3은 2,2-디페닐-1-피크릴히드라질(DPPH) 자유 라디칼 소거능을 나타낸 것이다. 도 3에서 서로 다른 알파벳은 통계적 유의차를 나타내고(p<0.05), 이하의 도면에서도 이와 같다.
도 4는 FRAP(Fluorescence recovery after photobleaching) 활성을 측정한 결과를 나타낸 것이다.
도 5는 세포독성 평가 결과를 나타낸 것이다.
도 6은 곤드레 마늘 발효물의 DPPH 라디칼 소거능을 나타낸 것이다.
도 7은 곤드레 마늘 발효물의 FRAP 활성을 나타낸 것이다.
도 8은 곤드레 마늘 발효물의 세포 독성 결과를 나타낸 것이다.
도 9는 곤드레 마늘 발효물의 NO 생성능을 나타낸 것이다.
도 10은 곤드레 마늘 발효물의 TNF-α 생성능을 나타낸 것이다.
도 11은 곤드레 마늘 발효물의 IL-1β 생성능을 나타낸 것이다.
도 12는 곤드레 마늘 발효물의 IL-10 생성능을 나타낸 것이다.Figure 1 shows a process for producing garlic and gondre lactic acid bacteria fermentation according to an embodiment of the present invention.
Figure 2 shows a manufacturing process of the gondre enzyme treatment extract according to an embodiment of the present invention.
Figure 3 shows 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging ability. Different alphabets in FIG. 3 represent statistically significant differences (p <0.05), and the same also applies to the following drawings.
Figure 4 shows the results of measuring Fluorescence recovery after photobleaching (FRAP) activity.
5 shows the results of cytotoxicity evaluation.
Figure 6 shows the DPPH radical scavenging ability of Gondre garlic fermentation.
Figure 7 shows the FRAP activity of Gondre garlic fermentation.
Figure 8 shows the cytotoxicity results of Gondre garlic fermentation.
Figure 9 shows the NO production ability of Gondre garlic fermentation.
Figure 10 shows the TNF-α producing ability of Gondre garlic fermentation.
Figure 11 shows the IL-1β production capacity of Gondre garlic fermentation.
Figure 12 shows the IL-10 production capacity of Gondre garlic fermentation.
본 발명은 마늘 추출물 및 곤드레 효소처리 추출물의 혼합물을 유산균으로 발효시킨, 마늘 및 곤드레 유산균 발효물에 관한 것이다.The present invention relates to garlic and gondry lactobacillus fermented product, in which a mixture of garlic extract and gondre enzyme treatment extract is fermented with lactic acid bacteria.
본 발명에서, 용어 "추출물"은 당업계에서 조추출물(crude extract)로 통용되는 의미를 갖지만, 광의적으로는 추출물을 추가적으로 분획(fractionation)한 분획물도 포함한다. In the present invention, the term "extract" has a meaning commonly used as a crude extract in the art, but broadly also includes a fraction additionally fractionating the extract.
즉, 상기 추출물은 추출 용매를 이용하여 얻은 것뿐만 아니라, 여기에 정제 과정을 추가적으로 적용하여 얻은 것도 포함한다. 예를 들어, 상기 추출물을 일정한 분자량 컷-오프 값을 갖는 한외 여과막을 통과시켜 얻은 분획, 다양한 크로마토그래피(크기, 전하, 소수성 또는 친화성에 따른 분리를 위해 제작된 것)에 의한 분리 등, 추가적으로 실시된 다양한 정제 방법을 통해 얻어진 분획도 상기 추출물에 포함되는 것이다.That is, the extract includes not only one obtained by using an extraction solvent but also one obtained by additionally applying a purification process thereto. For example, fractions obtained by passing the extract through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity), etc. Fractions obtained through various purification methods are included in the extract.
상기 추출 용매로는 극성 용매를 이용할 수 있는데, 상기 극성 용매로서 적합한 것은, 정제수, 알코올(바람직하게는, 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜), 아세트산, DMFO(dimethyl-formamide) 및 DMSO(dimethyl sulfoxide)를 포함하고, 보다 바람직하게는, 정제수, 탄소수 1-4의 무수 또는 함수 저급 알코올 (메탄올, 에탄올, 프로판올, 부탄올 등), 상기 저급 알코올과 정제수와의 혼합용매를 포함할 수 있으며, 가장 바람직하게는, 정제수, 메탄올, 에탄올 및 이의 혼합물일 수 있다.As the extraction solvent, a polar solvent may be used. Suitable solvents for the polar solvent include purified water and alcohol (preferably methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, and 1-pentane). Allol, 2-butoxyethanol or ethylene glycol), acetic acid, dimethyl-formamide (DMFO) and dimethyl sulfoxide (DMSO), more preferably purified water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, Ethanol, propanol, butanol, and the like), and a mixed solvent of the lower alcohol and purified water, and most preferably, purified water, methanol, ethanol, and mixtures thereof.
본 발명에서, 용어 "발효물"은 유산균주를 이용하여 발효과정을 거친 산물을 칭하는 것으로서, 발효후 고형분이 제거 또는 제거되지 않은 것이 모두 포함된다. In the present invention, the term "fermented product" refers to a product that has undergone a fermentation process using a lactic acid strain, and includes all solids that have not been removed or removed after fermentation.
본 발명의 상기 유산균 발효물에서, 상기 마늘 추출물 및 곤드레 효소처리 추출물의 혼합물은 상기 마늘 추출물 및 상기 곤드레 효소처리 추출물이 고형분 함량 기준으로 7:3~9:1의 부피비, 바람직하게는 7.5:2.5~8.5:1.5의 부피비, 보다 바람직하게는 8:2의 부피비로 혼합되어 있는 것일 수 있다.In the lactic acid bacteria fermented product of the present invention, the mixture of the garlic extract and gondre enzyme extract is a volume ratio of 7: 3-9: 1 based on the solid content of the garlic extract and the gondle enzyme treated extract, preferably 7.5: 2.5 It may be mixed at a volume ratio of ~ 8.5: 1.5, more preferably 8: 2.
본 발명의 상기 유산균 발효물에서, 상기 효소는 비스코자임(viscozyme)일 수 있으나, 이에 한정되는 것은 아니다.In the lactic acid bacterium fermentation product of the present invention, the enzyme may be biscozyme, but is not limited thereto.
본 발명의 상기 유산균 발효물에서, 상기 유산균은 류코노스톡 메센테로이데스(Leuconostoc mesenteroides), 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)으로 이루어진 군에서 선택되는 1종 이상일 수 있으나, 이에 한정되는 것은 아니다.In the lactic acid bacteria fermentation product of the present invention, the lactic acid bacteria are flow Pocono stock mesen teroyi des (Leuconostoc mesenteroides), Lactobacillus Planta room (Lactobacillus plantarum), Lactobacillus ash FIG pillar's (Lactobacillus acidophilus), Lactobacillus ramno suspension (Lactobacillus rhamnosus), Lactobacillus casei (Lactobacillus casei), Lactobacillus para casei (Lactobacillus paracasei), Lactobacillus ruteri (Lactobacillus reuteri), Lactobacillus salivarius (Lactobacillus salivarius), Bifidobacterium ronggeom (Bifidobacterium longum), BP Bifidobacterium breve ), Bifidobacterium lactis and Bifidobacterium bipiderum bifidum ) may be one or more selected from the group consisting of, but is not limited thereto.
본 발명의 상기 유산균 발효물에서, 상기 유산균은 류코노스톡 메센테로이데스일 수 있고, 보다 바람직하게는 류코노스톡 메센테로이데스 KCTC 13302일 수 있다.In the lactic acid bacteria fermentation product of the present invention, the lactic acid bacteria may be leukonostock mesenteroides, and more preferably may be leukonostock mesenteroides KCTC 13302.
또한, 본 발명은 (a) 마늘 추출물 및 곤드레 효소처리 추출물을 혼합하는 단계, 및 (b) 상기 혼합된 마늘 추출물 및 곤드레 효소처리 추출물의 혼합물에 유산균을 접종하고, 발효시키는 단계를 포함하는 마늘 및 곤드레 유산균 발효물의 제조방법에 관한 것이다.In addition, the present invention is a garlic comprising the step of inoculating and fermenting lactic acid bacteria in the mixture of (a) garlic extract and gondre enzyme treatment extract, and (b) the mixture of the garlic extract and gondle enzyme treatment extract; It relates to a production method of gondre lactic acid bacteria fermentation.
본 발명의 상기 유산균 발효물의 제조방법에서, 상기 마늘 추출물 및 곤드레 효소처리 추출물의 추출 용매로는 극성 용매를 이용할 수 있는데, 상기 극성 용매로서 적합한 것은, 정제수, 알코올(바람직하게는, 메탄올, 에탄올, 프로판올, 부탄올, 노말-프로판올, 이소-프로판올, 노말-부탄올, 1-펜탄올, 2-부톡시에탄올 또는 에틸렌글리콜), 아세트산, DMFO(dimethyl-formamide) 및 DMSO(dimethyl sulfoxide)를 포함하고, 보다 바람직하게는, 정제수, 탄소수 1-4의 무수 또는 함수 저급 알코올 (메탄올, 에탄올, 프로판올, 부탄올 등), 상기 저급 알코올과 정제수와의 혼합용매를 포함할 수 있으며, 가장 바람직하게는, 정제수, 메탄올, 에탄올 및 이의 혼합물일 수 있다.In the production method of the lactic acid bacteria fermentation product of the present invention, as the extraction solvent of the garlic extract and gondre enzyme treatment extract, a polar solvent may be used. Suitable as the polar solvent is purified water, alcohol (preferably methanol, ethanol, Propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol), acetic acid, dimethyl-formamide (DMFO) and dimethyl sulfoxide (DMSO) Preferably, purified water, anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), a mixed solvent of the lower alcohol and purified water, and most preferably, purified water, methanol , Ethanol and mixtures thereof.
본 발명의 상기 유산균 발효물의 제조방법에서, 상기 마늘 추출물은 마늘을 중량비로 2~3배, 바람직하게는 2.5배의 물에 침지시킨 후, 80~100℃, 바람직하게는 85~95℃의 열을 가하여 바람직하게는 3~5시간 동안 추출한 다음, 8~12 브릭스, 바람직하게는 9~11 브릭스로 농축시키는 단계를 포함하여 제조될 수 있다.In the method for producing the lactic acid bacteria fermentation product of the present invention, the garlic extract is immersed in 2 to 3 times, preferably 2.5 times, water by weight of garlic, and then heated to 80 to 100 ° C, preferably 85 to 95 ° C. Extraction is preferably performed for 3 to 5 hours, followed by concentration to 8 to 12 brix, preferably 9 to 11 brix.
본 발명의 일 실시예에 따른 마늘 추출물의 제조방법은 도 1에 나타낸 바와 같다.Garlic extract manufacturing method according to an embodiment of the present invention is as shown in FIG.
본 발명의 상기 유산균 발효물의 제조방법에서, 상기 곤드레 효소처리 추출물은 건조시킨 곤드레를 중량비로 5~15배, 바람직하게는 8~12배, 보다 바람직하게는 9~11배의 물에 침지시킨 후, 80~100℃, 바람직하게는 85~95℃의 열을 가하여 바람직하게는 3~5시간 동안 추출한 다음 여과하는 단계; 및 상기 여과한 추출물을 8~12 브릭스로, 바람직하게는 9~11 브릭스 농축시킨 후, 40~55℃, 바람직하게는 45~55℃에서 5~8시간, 바람직하게는 5~7시간 동안 효소, 바람직하게는 비스코자임(viscozyme)을 처리하는 단계를 포함하여 제조될 수 있다.In the production method of the lactic acid bacteria fermentation product of the present invention, the gondre enzyme treatment extract is immersed in 5 to 15 times, preferably 8 to 12 times, more preferably 9 to 11 times water by weight of dried gondre , 80-100 ° C., preferably 85-95 ° C., followed by extraction, preferably for 3-5 hours, followed by filtration; And the filtered extract is concentrated to 8-12 briquettes, preferably 9-11 briquettes, followed by enzymes at 40-55 ° C., preferably 45-55 ° C. for 5-8 hours, preferably 5-7 hours. Preferably, it may be prepared, including the step of treating the viscozyme.
본 발명의 일 실시예에 따른 곤드레 효소처리 추출물의 제조방법은 도 2에 나타낸 바와 같다.The preparation method of gondre enzyme treatment extract according to an embodiment of the present invention is as shown in FIG.
본 발명의 상기 유산균 발효물의 제조방법에서, 상기 (a) 단계는 상기 마늘 추출물 및 상기 곤드레 효소처리 추출물을 고형분 함량 기준으로 7:3~9:1, 바람직하게는 7.5:2.5~8.5:1.5의 부피비, 보다 바람직하게는 8:2의 부피비로 혼합할 수 있다.In the production method of the lactic acid bacteria fermentation product of the present invention, the step (a) is based on the solid content of the garlic extract and gondre enzyme treatment extract 7: 3 ~ 9: 1, preferably 7.5: 2.5 ~ 8.5: 1.5 It may be mixed in a volume ratio, more preferably in a volume ratio of 8: 2.
본 발명의 상기 유산균 발효물의 제조방법에서, 상기 유산균은 류코노스톡 메센테로이데스(Leuconostoc mesenteroides), 락토바실러스 플란타룸(Lactobacillus plantarum), 락토바실러스 애시도필러스(Lactobacillus acidophilus), 락토바실러스 람노서스(Lactobacillus rhamnosus), 락토바실러스 카제이(Lactobacillus casei), 락토바실러스 파라카제이(Lactobacillus paracasei), 락토바실러스 루테리(Lactobacillus reuteri), 락토바실러스 살리바리우스(Lactobacillus salivarius), 비피도박테리움 롱검(Bifidobacterium longum), 비피도박테리움 브레브(Bifidobacterium breve), 비피도박테리움 락티스(Bifidobacterium lactis) 및 비피도박테리움 비피덤(Bifidobacterium bifidum)으로 이루어진 군에서 선택되는 1종 이상일 수 있으나, 이에 한정되는 것은 아니다.In the method for preparing the lactic acid bacteria fermentation product of the present invention, the lactic acid bacteria is Leuconostoc mesenteroides , Lactobacillus plantarum , Lactobacillus acidophilus , Lactobacillus acidophilus , Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus casei (Lactobacillus casei), Lactobacillus para casei (Lactobacillus paracasei), Lactobacillus ruteri (Lactobacillus reuteri), Lactobacillus salivarius (Lactobacillus salivarius), Bifidobacterium ronggeom (Bifidobacterium longum) , Bifidobacterium breb breve ), Bifidobacterium lactis and Bifidobacterium bipiderum bifidum ) may be one or more selected from the group consisting of, but is not limited thereto.
본 발명의 상기 유산균 발효물의 제조방법에서, 상기 유산균은 류코노스톡 메센테로이데스일 수 있고, 보다 바람직하게는 류코노스톡 메센테로이데스 KCTC 13302일 수 있다.In the method for preparing the lactic acid bacteria fermentation product of the present invention, the lactic acid bacteria may be leukonostock mesenteroides, and more preferably may be leukonostock mesenteroides KCTC 13302.
본 발명의 상기 유산균 발효물의 제조방법에서, 상기 발효는 36~38℃, 바람직하게는 37℃에서 36~60시간, 바람직하게는 46~50시간, 보다 바람직하게는 48시간 동안 침지 발효할 수 있다.In the production method of the lactic acid bacteria fermentation product of the present invention, the fermentation may be immersed for 36 to 60 hours, preferably 46 to 50 hours, more preferably 48 hours at 36 ~ 38 ℃, preferably 37 ℃. .
본 발명의 상기 유산균 발효물의 제조방법은 상기 (b) 단계 후에 멸균하고, 여과한 다음 농축하는 단계를 더 포함할 수 있다. 상기 멸균은 바람직하게는 100℃에서 1시간 동안 수행할 수 있고, 상기 농축은 25~35 브릭스, 바람직하게는 30 브릭스로 농축시킬 수 있으나, 이에 한정되는 것은 아니다.The method for preparing the lactic acid bacteria fermentation product of the present invention may further include sterilizing, filtering and concentrating after the step (b). The sterilization may be preferably performed at 100 ° C. for 1 hour, and the concentration may be concentrated to 25 to 35 brix, preferably 30 brix, but is not limited thereto.
또한, 본 발명은 마늘 및 곤드레 유산균 발효물을 포함하는 항산화 및 면역개선용 조성물에 관한 것이다.In addition, the present invention relates to an antioxidant and immune-improving composition comprising garlic and gondre lactic acid bacteria fermentation.
본 발명에서, 용어 "항산화(antioxidation)"는 산화를 억제하는 작용을 의미하고, 용어 "면역개선(immune improvement)"은 생체내 면역 시스템의 면역 반응 또는 활성을 증가시키는 것을 의미한다.In the present invention, the term "antioxidation" means the action of inhibiting oxidation, and the term "immune improvement" means increasing the immune response or activity of the immune system in vivo.
본 발명에서, 용어 "건강기능식품(health functional food)"은 인체에 유용한 기능을 갖는 원료를 사용하여 정제, 캅셀, 분말, 과립, 액상, 환 등의 형태로 가공된 보조 식품을 의미한다.In the present invention, the term "health functional food" (health functional food) means a supplementary food processed in the form of tablets, capsules, powders, granules, liquid, pills, etc. using a raw material having a useful function to the human body.
본 발명의 상기 항산화 및 면역개선용 조성물에서, 상기 조성물은 건강기능식품일 수 있다. In the antioxidant and immune improving composition of the present invention, the composition may be a dietary supplement.
본 발명의 상기 항산화 및 면역개선용 조성물에서, 상기 조성물은 음료일 수 있으나, 이에 한정되는 것은 아니다.In the antioxidant and immune-improving composition of the present invention, the composition may be a beverage, but is not limited thereto.
상기 건강기능식품으로는 본 발명의 마늘 및 곤드레 유산균 발효물을 차, 쥬스 및 드링크의 형태로 제조하여 음용하도록 하거나, 과립화, 캡슐화 및 분말화하여 섭취할 수 있다. The health functional food can be prepared by drinking the garlic and gondry lactobacillus fermented product of the present invention in the form of tea, juice and drink, or granulated, encapsulated and powdered.
또한, 본 발명의 유산균 발효물과 항산화 및 면역기능 증진효과가 있다고 알려진 공지의 물질 또는 활성 성분과 함께 혼합하여 조성물의 형태로 제조할 수 있다.In addition, it can be prepared in the form of a composition by mixing with the lactic acid bacteria fermented product of the present invention and known substances or active ingredients known to have antioxidant and immune function enhancing effects.
본 발명의 상기 건강기능식품은 유효성분으로서 상기 유산균 발효물 뿐만 아니라, 식품 제조시에 통상적으로 첨가되는 성분을 포함하며, 예를 들어, 단백질, 탄수화물, 지방, 영양소, 조미제 및 향미제를 포함한다. The health functional food of the present invention includes not only the lactic acid bacteria fermented product as an active ingredient, but also components commonly added during food production, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings, and flavoring agents. do.
상기 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스, 올리고당 등; 및 폴리사카라이드, 예를 들어 덱스트린, 사이클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜을 들 수 있으나, 이에 한정되는 것은 아니다. Examples of such carbohydrates are monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, erythritol, and the like.
상기 향미제로는 천연 향미제(타우마틴; 레바우디오시드 A, 글리시르히진 등과 같은 스테비아 추출물) 및 합성 향미제(사카린, 아스파르탐 등)를 사용할 수 있으나, 이에 한정되는 것은 아니다. As the flavoring agent, natural flavoring agents (tautin; stevia extracts such as rebaudioside A, glycyrgin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) may be used, but are not limited thereto.
예를 들어, 본 발명의 상기 건강기능식품 조성물이 음료 조성물인 경우에는 본 발명의 상기 유산균 발효물 이외에 구연산, 액상과당, 설탕, 포도당, 초산, 사과산, 사과농축액, 배농축액, 당귀농축액, 대추농축액, 감초농축액, 오미자농축액, 복합황금추출물 등을 추가로 포함시킬 수 있다.For example, when the health functional food composition of the present invention is a beverage composition citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, apple concentrate, pear concentrate, sugar concentrate, jujube concentrate in addition to the lactic acid bacteria fermented product of the present invention , Licorice concentrate, Schisandra chinensis concentrate, complex golden extract may be further included.
본 발명의 상기 항산화 및 면역개선용 조성물에서, 상기 조성물은 약제학적으로 허용되는 담체를 더 포함하는 약학 조성물일 수 있다.In the antioxidant and immune-improving composition of the present invention, the composition may be a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
본 발명의 상기 항산화 및 면역개선용 조성물에서, 상기 약학 조성물은 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으나, 이에 한정되는 것은 아니다. In the antioxidant and immune-improving composition of the present invention, the pharmaceutical composition is in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, external preparations and sterile injectable solutions according to a conventional method. It can be used in the formulation, but is not limited thereto.
본 발명의 상기 항산화 및 면역개선용 조성물에서, 상기 조성물은 화장료 조성물일 수 있다.In the antioxidant and immune improving composition of the present invention, the composition may be a cosmetic composition.
본 발명의 상기 항산화 및 면역개선용 조성물에서, 상기 화장료 조성물은 본 발명이 속하는 기술분야에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있는데, 예를 들어 크림, 로션, 스킨, 유연화장수, 수렴화장수, 파운데이션, 클린징, 세안제, 비누, 미용액 등의 제형으로 제제화될 수 있으나, 이에 한정되는 것은 아니다.In the antioxidant and immune improving composition of the present invention, the cosmetic composition may be prepared in any formulation commonly prepared in the art, for example, creams, lotions, skins, softening, converging cosmetics Formulations, such as foundation, cleansing, face wash, soap, essence, but are not limited thereto.
본 발명의 상기 항산화 및 면역개선용 조성물 중 상기 유산균 발효물의 바람직한 함량은 0.01 내지 50 중량%이지만, 이에 한정되는 것은 아니다.Preferred content of the lactic acid bacteria fermentation product in the antioxidant and immune-improving composition of the present invention is 0.01 to 50% by weight, but is not limited thereto.
이하, 본 발명을 실시예를 통하여 상세히 설명한다. 그러나 이들 실시예는 본 발명을 구체적으로 설명하기 위한 것일 뿐, 본 발명의 범위가 이들 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail through examples. However, these examples are only for illustrating the present invention in detail, and the scope of the present invention is not limited by these examples.
<실시예 1> (마늘 및 곤드레 원료의 최적조건 확립)Example 1 Establishment of Optimum Conditions for Garlic and Gondre Raw Materials
1. 실험 방법1. Experiment Method
1-1. 시료1-1. sample
마늘(Allium sativum)과 효소처리된 곤드레는 ㈜이롬(Erom company Limited, Korea)에서 구입하였다. 류코노스톡 메센테로이데스(Leuconostoc mesenteroides) KCTC 13302는 강원대학교 식품생명공학과에서 입수하였다. 상기 균주는 이전 실험에서 생물학적으로 가장 강한 활성을 갖는 마늘 제품을 생산했기 때문에 선택되었다.Garlic ( Allium sativum ) and enzyme-treated gondre were purchased from Erom company Limited, Korea. Leuconostoc mesenteroides ) KCTC 13302 was obtained from the Department of Food and Biotechnology, Kangwon National University. The strain was chosen because in the previous experiments it produced garlic products with the strongest biological activity.
1-2. 화학약품 및 시약1-2. Chemicals and Reagents
삼염화 초산(TCA), 갈산 및 Folin-Ciocalteau's 시약은 Sigma-Aldrich, Inc.(한국)에서 조달하였다. 디니트로페닐 하이드라진(DNPH)은 ACROS Organics (New Jersey, USA)에서, 과산화수소, 메탄올 및 FeCl3는 BDH Chemicals Ltd. (Poole, England)에서 구입하였고, 티오우레아(thiourea), CuSO4·5H2O, H2SO4, 탄산나트륨, AlCl3, 칼륨 아세테이트, 트리스 염산 완충액, FeSO4, 페리시안화 칼륨 및 염화제2철은 분석 등급이었고, 물은 유리 증류(glass distillation)되었다.Trichloroacetic acid (TCA), gallic acid and Folin-Ciocalteau's reagents were sourced from Sigma-Aldrich, Inc. (Korea). Dinitrophenyl hydrazine (DNPH) is from ACROS Organics (New Jersey, USA), while hydrogen peroxide, methanol and FeCl 3 are BDH Chemicals Ltd. Purchased from Poole, England, and thiourea, CuSO 4 · 5H 2 O, H 2 SO 4 , sodium carbonate, AlCl 3 , potassium acetate, tris hydrochloric acid buffer, FeSO 4 , potassium ferricyanide and ferric chloride were analyzed Grade, and water was glass distillation.
1-3. 균주 배양1-3. Strain culture
류코노스톡 메센테로이데스 KCTC 13302를 MRS 브로쓰 배지에서 37℃에서 36시간 동안 생장시켰다. 배양물을 원심분리하여 세포 펠릿을 얻은 다음, 재증류수(double distilled water)로 2회 세척하였다. 그런 다음 세포를 증류수로 희석하고 사용할 때까지 4℃에서 보관하였다.Leukonostock Mesenteroides KCTC 13302 was grown in MRS broth medium at 37 ° C. for 36 hours. The cultures were centrifuged to obtain cell pellets, which were then washed twice with double distilled water. Cells were then diluted with distilled water and stored at 4 ° C. until use.
1-4. 마늘과 1-4. Garlic and 곤드레의Gondre 준비 Ready
마늘을 껍질을 벗기고, 세척한 후, 믹서기를 사용하여 층류 후드(laminar flow hood)에서 건조시키고, 블렌더를 사용하여 갈았다. 마늘 100g을 전자저울로 칭량하고 증류수 250mL와 혼합하였다. The garlic was peeled, washed, dried in a laminar flow hood using a blender and ground using a blender. 100 g of garlic was weighed with an electronic balance and mixed with 250 mL of distilled water.
상기에서 얻은 혼합물을 100℃에서 1시간 동안 쪄서 50℃로 냉각시켰다. 0.5mL의 셀룰라아제를 30분 동안 첨가한 후, 0.75 mL의 프로테아제를 1시간 동안 첨가하였다. 1.25mL의 아밀라아제를 첨가하고, 70℃에서 1시간 동안 가열하였다. The mixture obtained above was steamed at 100 ° C. for 1 hour and cooled to 50 ° C. 0.5 mL of cellulase was added for 30 minutes, followed by 0.75 mL of protease for 1 hour. 1.25 mL of amylase was added and heated at 70 ° C. for 1 hour.
그 후 효소를 90℃에서 30분 동안 온도를 증가시켜 비활성화시키고, 혼합물을 농축하여 7 브릭스를 얻었다. 시료를 17%로 농축시켜 10 브릭스로 조정한 후, 동결건조시켰다.The enzyme was then deactivated by increasing the temperature at 90 ° C. for 30 minutes and the mixture was concentrated to give 7 brics. The sample was concentrated to 17%, adjusted to 10 brix and then lyophilized.
곤드레를 제조하기 위하여, 곤드레 원물을 90℃에서 2회 물로 추출하고 여과하였다. 그 후 시료를 10 브릭스로 농축하고, 50℃에서 6시간 동안 0.5% viscozyme(v/v)로 처리하였다. 그 후 시료를 냉각하고 동결 건조시켜, 사용할 때까지 영하 20℃에서 보관하였다 (도 2 참조).To prepare the gondres, the gondres originals were extracted with water twice at 90 ° C. and filtered. The sample was then concentrated to 10 brix and treated with 0.5% viscozyme (v / v) at 50 ° C. for 6 hours. The samples were then cooled and lyophilized and stored at minus 20 ° C. until use (see FIG. 2).
마늘과 곤드레의 비율을 각각 90:10, 80:20, 50:50, 100 :0 및 0:100의 부피비로 혼합하고, 고압증기 멸균하였다.The ratio of garlic and gondre was mixed in volume ratios of 90:10, 80:20, 50:50, 100: 0 and 0: 100, respectively, and autoclaved.
1-5. 곤드레 마늘 1-5. Gondre garlic 발효물의Fermented product 제조 Produce
다양한 비율의 마늘과 곤드레(90:10, 80:20, 50:50의 부피비)에 0.1% Leuconostoc mesenteroides KCTC 13302(v/v)를 증류수로 접종하였다. 시료를 37℃ 에서 48시간 동안 배양하였다. 그 후 시료를 100℃에서 1시간 동안 가열하여 멸균시키고, 30 브릭스로 농축시켰다. 최종 pH는 5.4~5.7이었다.Garlic and gondles (volume ratios of 90:10, 80:20, 50:50) were inoculated with 0.1% Leuconostoc mesenteroides KCTC 13302 (v / v) with distilled water. Samples were incubated at 37 ° C. for 48 hours. The sample was then sterilized by heating at 100 ° C. for 1 hour and concentrated to 30 brics. Final pH was 5.4-5.7.
1-6. 생리활성 평가를 위한 시료1-6. Samples for Bioactivity Assessment
생곤드레(S1), 효소처리 곤드레(S2), 생마늘(S3), 발효마늘(S4), 효소처리 곤드레 10%(0.1g)와 발효마늘 90%(0.9g) 혼합물(S5), 효소처리 곤드레 20%(0.2g)와 발효마늘 80%(0.8g) 혼합물(S6), 마늘 90%와 효소처리 곤드레 10% 혼합물의 발효물(S7), 마늘 80%와 효소처리 곤드레 20% 혼합물의 발효물(S8), 효소처리 곤드레 50%와 발효마늘 50%의 혼합물(S9) 및 마늘 50%와 효소처리 곤드레 50% 혼합물의 발효물(S10)을 대상으로 하여 이하의 생리활성 평가를 하였다.Raw Gondre (S1), Enzyme Gondre (S2), Raw Garlic (S3), Fermented Garlic (S4),
1-7. 총 페놀 함량의 측정1-7. Determination of Total Phenolic Content
총 페놀 함량은 약간의 수정을 가한 Singleton, Orthofer, & Lamuela-Raventos, 1999(Methods in enzymology, Vol. 299, pp. 152-178)의 방법에 따라 결정되었다. 수성 추출물 중에서 시료(시료:물=1:100)를 채취하여 여과하고 100㎕를 10% Folin-Ciocalteau's 시약(v/v) 2.5mL로 시험관 내에서 산화시킨 후, 7.5% 소디움카보네이트 2.0mL를 첨가하여 중화시켰다.Total phenolic content was determined according to the method of Singleton, Orthofer, & Lamuela-Raventos, 1999 (Methods in enzymology, Vol. 299, pp. 152-178) with some modifications. A sample (sample: water = 1: 100) was taken from the aqueous extract, filtered, and 100 µl was oxidized in vitro with 2.5 mL of 10% Folin-Ciocalteau's reagent (v / v), followed by addition of 2.0 mL of 7.5% sodium carbonate. Neutralized.
반응 혼합물을 45℃에서 40분간 배양하고, 바이오스펙트로미터(Eppendorf Biospectrometer® fluorescence, Eppendorf Korea, Korea)을 이용하여 765nm에서 흡광도를 측정하였다. 이어서, 총페놀 함량은 갈산 흡광도의 표준곡선으로부터 계산하여 갈산 당량(gallic acid equivalent)으로 나타내었다. The reaction mixture was incubated at 45 ° C. for 40 minutes and the absorbance was measured at 765 nm using a Biospectrometer (Eppendorf Biospectrometer ® fluorescence, Eppendorf Korea, Korea). The total phenolic content was then expressed as gallic acid equivalent calculated from the standard curve of gallic acid absorbance.
1-8. 총 플라보노이드 함량1-8. Total Flavonoid Content
조 추출물의 총 플라보노이드 함량은 염화알루미늄 비색법(Chang, Yang, Wen, & Chern, 2002, Journal of food and drug analysis, 10(3))에 의해 결정되었다. The total flavonoid content of the crude extract was determined by aluminum chloride colorimetric method (Chang, Yang, Wen, & Chern, 2002, Journal of food and drug analysis, 10 (3)).
간단히 말하면, 50μL의 시료(1 mg/mL 에탄올)를 메탄올로 1 mL까지 만들고, 4 mL의 증류수와 섞은 다음 0.3 mL의 5% NaNO2 용액과 혼합하였다. 10% AlCl3 용액 0.3 mL를 5분간 배양한 후 첨가하고, 혼합물을 6분간 방치하였다. In brief, 50 μL of sample (1 mg / mL ethanol) was made up to 1 mL with methanol, mixed with 4 mL of distilled water and then mixed with 0.3 mL of 5% NaNO 2 solution. 0.3 mL of 10% AlCl 3 solution was incubated for 5 minutes and then added, and the mixture was left for 6 minutes.
그런 다음, 1 mol/L NaOH 용액 2 mL를 첨가하고 혼합물의 최종 부피를 재증류수로 10 mL가 되게 한 후, 혼합물을 15분간 방치하고 510nm에서 흡광도를 측정 하였다. Then, 2 mL of 1 mol / L NaOH solution was added and the final volume of the mixture was brought to 10 mL with distilled water, the mixture was left for 15 minutes and the absorbance was measured at 510 nm.
총 플라보노이드 함량은 검량선으로부터 계산하였고, 그 결과는 건조 중량 (g) 당 mg 루틴 당량으로 나타내었다. Total flavonoid content was calculated from the calibration curve and the results are expressed in mg routine equivalents per gram of dry weight.
1-9. 항산화 활성1-9. Antioxidant activity
1-9-1. 2,2-디페닐-1-1-9-1. 2,2-diphenyl-1- 피크릴하이드라질Picrylhydrazyl 자유 라디칼 Free radicals 소거능Scavenging power (( DPPHDPPH ))
시료의 수소 원자 또는 전자 공여능은 보라색의 DPPH 메탄올 용액의 표백(bleaching)으로부터 측정되었다. DPPH(1,1-diphenyl-2-picrylhydrazyl) 유리 라디칼에 대한 추출물의 자유 라디칼 소거능은 Gyamfi, Yonamine, & Aniya의 방법(The Vascular System, 32(6), 661-667 (1999))으로 평가하였다. The hydrogen atom or electron donating ability of the sample was measured from bleaching of the purple DPPH methanol solution. The free radical scavenging ability of the extract against DPPH (1,1-diphenyl-2-picrylhydrazyl) free radicals was evaluated by the method of Gyamfi, Yonamine, & Aniya (The Vascular System, 32 (6), 661-667 (1999)). .
추출물(1 mL)의 희석액을 DPPH 라디칼을 함유하는 0.4 mM 메탄올 용액 1 mL과 혼합하고, 혼합물을 어두운 곳에서 30분간 방치한 후, 바이오스펙트로미터(Eppendorf Biospectrometer® fluorescence, Eppendorf Korea)를 이용하여 516nm에서 흡광도를 측정하였다. The dilution of the extract (1 mL) was mixed with 1 mL of 0.4 mM methanol solution containing DPPH radicals, and the mixture was left in the dark for 30 minutes, and then 516 nm using a Biospectrometer (Eppendorf Biospectrometer ® fluorescence, Eppendorf Korea). Absorbance was measured at.
시료의 라디칼 소거능(A1)은 사용된 음성 대조군인 물에서의 라디칼 저해(A0)와 비교하여, 시료에 의해 저해된 DPPH 자유 라디칼의 백분율로 계산하였다. DPPH 저해는 다음 식으로 계산하였다.The radical scavenging ability (A 1 ) of the sample was calculated as the percentage of DPPH free radicals inhibited by the sample compared to radical inhibition (A 0 ) in water, the negative control used. DPPH inhibition was calculated by the following equation.
DPPH 소거 효과(% 저해) = ((A0-A1) / A0) × 100DPPH elimination effect (% inhibition) = ((A 0 -A 1 ) / A 0 ) × 100
1-9-2. 환원성의 결정1-9-2. Reducibility
추출물의 환원성은 FeCl3 용액을 환원시키는 추출물의 능력을 평가하여 결정하였다(Zhao et al., 2008, Food Chemistry, 107(1), 296-304). 분액 추출물 2.5 mL를 200 mM 인산나트륨 완충액(pH 6.6) 2.5 mL 및 1% 페리시안화 칼륨 2.5 mL와 혼합하였다. The reducibility of the extract was determined by assessing the ability of the extract to reduce the FeCl 3 solution (Zhao et al., 2008, Food Chemistry, 107 (1), 296-304). 2.5 mL aliquot extracts were mixed with 2.5
혼합물을 50℃에서 20분 동안 배양한 후, 2.5 mL의 10% 트리클로로아세트산을 첨가하였다. 이 혼합물을 45 x g에서 10분간 원심분리하고, 5 mL의 상층액을 같은 부피의 물과 혼합한 후 0.1% 염화제이철 1 mL를 첨가하였다. The mixture was incubated at 50 ° C. for 20 minutes, then 2.5 mL of 10% trichloroacetic acid was added. The mixture was centrifuged at 45 x g for 10 minutes, 5 mL of the supernatant was mixed with an equal volume of water and then 1 mL of 0.1% ferric chloride was added.
흡광도는 바이오스펙트로미터(Eppendorf Biospectrometer® fluorescence, Eppendorf Korea, Korea)으로 700nm에서 측정하였다. 이때 아스코르브산을 양성 대조군으로 사용하였다. 이어서 철분 환원 항산화(frttic reducing antioxidation) 특성을 계산하였다.Absorbance was measured at 700 nm with a BioSpectrometer (Eppendorf Biospectrometer ® fluorescence, Eppendorf Korea, Korea). Ascorbic acid was used as a positive control. The iron reducing antioxidation properties were then calculated.
1-10. 세포독성 평가1-10. Cytotoxicity Assessment
곤드레와 마늘을 이용하여 조제한 상기 시료 10종에 대하여 세포독성 여부를 확인하기 위하여, 시험관 내(in vitro)에서 세포생존능 어세이(XTT assay)를 수행하였다.In order to confirm the cytotoxicity of the 10 samples prepared using Gondre and garlic, a cell viability assay (XTT assay) was performed in vitro.
상기 XTT 어세이는 포식세포를 1X104 세포/웰의 밀도로 96-웰 플레이트에 첨가하고 상기 시료의 에탄올 추출물dmf 첨가하여 3일간 배양한 후, XTT 용액 50㎕를 각각의 웰에 첨가하고 4시간 배양 후 ELISA reader(Molecular Devices, CA, USA)를 이용하여 450nm에서 흡광도를 확인하는 방법으로 수행하였다.The XTT Assay is a macrophage of 1 × 10 4 Cells and wells were added to 96-well plates and incubated for 3 days with the ethanol extract dmf of the sample. 50 μl of XTT solution was added to each well and 4 hours of incubation followed by ELISA reader (Molecular Devices, CA, USA) was used to determine the absorbance at 450nm.
1-11. NO 1-11. NO 생성능Generating ability 측정 Measure
곤드레와 마늘을 이용하여 조제한 상기 시료 10종에 대하여, 시료가 대식세포를 활성화시켜 NO 생성에 미치는 영향을 보기 위하여, Raw 264.7 세포에 각각의 시료를 50, 100, 200 μg/mL 농도로 처리하여 NO(nitric oxide) 생성능을 측정하였다.For the 10 samples prepared using gondre and garlic, each sample was treated at 50, 100, 200 μg / mL concentration in Raw 264.7 cells in order to see the effect of the samples on NO production by activating macrophages. NO (nitric oxide) production capacity was measured.
2. 실험 결과2. Experimental Results
2-1. 총 페놀 및 총 플라보노이드 화합물 분석2-1. Total Phenolic and Total Flavonoid Compound Analysis
곤드레와 마늘을 이용하여 조제한 상기 시료 10종, 즉 생곤드레(S1), 효소처리 곤드레(S2), 생마늘(S3), 발효마늘(S4), 효소처리 곤드레 10%(0.1g)와 발효마늘 90%(0.9g) 혼합물(S5), 효소처리 곤드레 20%(0.2g)와 발효마늘 80%(0.8g) 혼합물(S6), 마늘 90%와 효소처리 곤드레 10% 혼합물의 발효물(S7), 마늘 80%와 효소처리 곤드레 20% 혼합물의 발효물(S8), 효소처리 곤드레 50%와 발효마늘 50%의 혼합물(S9) 및 마늘 50%와 효소처리 곤드레 50% 혼합물의 발효물(S10)을 대상으로 하여 총 페놀 및 총 플라보노이드 화합물을 분석한 결과를 하기 표 1에 나타내었다.10 kinds of samples prepared by using gondre and garlic, namely raw gondre (S1), enzyme-treated gondre (S2), fresh garlic (S3), fermented garlic (S4), fermented
상기 표 1에서 보는 바와 같이, 총 페놀의 함량은 시료별로 S1, S2, S9, S8, S5의 순으로 함량이 높은 것으로 나타났으며, 총 플라보노이드 함량은 시료별로 S2, S9, S5, S6, S8의 순으로 높은 것으로 나타 났다.As shown in Table 1, the total phenol content was found to be high in the order of S1, S2, S9, S8, S5 for each sample, the total flavonoid content is S2, S9, S5, S6, S8 for each sample Appeared to be in the highest order.
마늘 발효물의 개별 원료 보다 곤드레 효소처리 원료와 마늘 발효물의 혼합물이 총 페놀의 함량이 보다 증가한 것으로 확인되었으며, 곤드레 효소처리 원료의 함량비가 증가할수록 보다 증가하는 것으로 나타났다.The total phenolic content of the gondre-enzyme-treated raw material and the garlic fermented product was found to be higher than the individual raw materials of the garlic fermented product.
2-2. 항산화 활성2-2. Antioxidant activity
2-2-1 2,2-디페닐-1-2-2-1 2,2-diphenyl-1- 피크릴하이드라질Picrylhydrazyl (( DPPHDPPH ) 자유 라디칼 Free radical 소거능Scavenging power
각 시료의 라디칼 소거능을 확인하기 위하여 L-아스코르브산(AsA)을 표준물지로 대조하여 10, 50, 100 ㎍/㎖ 농도로 조제하여 DPPH 라디칼 소거능을 비교한 결과를 도 3에 나타내었다. In order to confirm the radical scavenging ability of each sample, L-ascorbic acid (AsA) was prepared at a concentration of 10, 50, and 100 µg / ml, compared to a standard paper, and the results of comparing DPPH radical scavenging ability are shown in FIG. 3.
도 3에서 보는 바와 같이, 모든 시료가 전반적으로 항산화 활성이 우수한 것으로 평가 되었으며, 특히 S1, S2, S9, S6, 및 S8 시료가 DPPH 라디칼 소거능이 우수한 것으로 나타났다.As shown in Figure 3, all samples were evaluated as excellent overall antioxidant activity, in particular S1, S2, S9, S6, and S8 samples were shown to have excellent DPPH radical scavenging ability.
2-2-2. 환원성의 결정2-2-2. Reducibility
FRAP 활성을 측정하여 각 샘플의 항산화 능력을 평가하였는데, FRAP 활성을 측정한 결과를 도 4에 나타내었다. FRAP activity was measured to evaluate the antioxidant capacity of each sample, and the results of measuring FRAP activity are shown in FIG. 4.
도 4에서 보는 바와 같이, S1, S9, S2, S8 순으로 항산화능이 높은 것으로 나타났다. 또한 마늘 발효물 보다 마늘 발효물과 곤드레를 혼합한 경우 항산화력이 더욱 높아지는 것을 확인하였으며, 곤드레 함량이 높을수록 항산화능이 더 높게 증가하는 것으로 나타났다.As shown in Figure 4, S1, S9, S2, S8 was found to have high antioxidant capacity in order. In addition, when the garlic fermentation and gondre were mixed than the garlic fermentation, the antioxidant power was confirmed to be higher, and the higher the gondre content, the higher the antioxidant activity.
총 페놀 화합물과 플라보노이드의 함량 분석 결과와 DPPH 라디칼 소거능 및 FRAP 분석을 통한 항산화 활성과 비교해 보면, 항산화력은 플라보노이드의 함량 보다 총 페놀 화합물의 함량에 더 높은 상관관계가 있는 것으로 보여진다.Compared with the results of the analysis of total phenolic compounds and flavonoids and the antioxidant activity through DPPH radical scavenging activity and FRAP analysis, the antioxidant power was shown to be higher correlated with the total phenolic compound content than the flavonoid content.
2-3. 세포독성2-3. Cytotoxicity
XTT 어세이를 이용한 세포독성 측정 결과를 도 5에 나타내었다. The cytotoxicity measurement results using the XTT assay are shown in FIG. 5.
도 5에서 보는 바와 같이, 상기 시료 10종은 50, 100, 200 μg/mL 농도에서 모두 90% 이상의 세포 생존율을 나타내어, 세포독성에 영향을 미치지 않는 것으로 평가되었다.As shown in FIG. 5, the 10 samples showed cell viability of 90% or more at 50, 100, and 200 μg / mL concentrations, and were evaluated as having no effect on cytotoxicity.
2-4. NO 2-4. NO 생성능Generating ability
실험 결과, 각각의 시료 처치에 따라 농도 의존적으로 NO 생성능이 증가하는 경향을 나타내었다. 특히 시료 중 S8이 5.35, 6.43, 8.23 μM의 농도로 NO를 생성한 것으로 나타나, 다른 시료 보다 유의하게 면역활성이 높은 것으로 평가되었다.As a result of the experiments, the concentration of NO production increased with concentration of each sample treatment. In particular, S8 produced NO at concentrations of 5.35, 6.43, and 8.23 μM, indicating that the immune activity was significantly higher than that of other samples.
3. 고찰3. Consideration
상기와 같이, 총 페놀 화합물 및 총 플라보노이드의 함량, DPPH 라디칼 소거능 및 FRAP 분석을 통한 항산화 활성 평가와 대식세포의 NO 생성능을 지표로 하여 면역활성을 평가하였는 바, S1에서 S10의 각각의 시료에 대하여 모든 시료는 처치 농도가 증가할수록 항산화 활성 및 면역증진 효능이 증가하는 것으로 나타났으며, 특히 마늘 발효물 또는 곤드레 효소처리물의 단독 원료 보다는 두 원료를 혼합한 경우 활성이 더욱 높은 것으로 나타났다.As described above, the total phenolic compound and total flavonoid content, DPPH radical scavenging ability and antioxidant activity evaluation by FRAP analysis and macrophage NO production ability as an indicator was evaluated for immunological activity, for each sample of S1 to S10 All samples showed increased antioxidant activity and immunostimulating effect as treatment concentrations increased, especially when the two ingredients were mixed rather than garlic fermented or Gondre enzyme treatment alone.
곤드레의 경우 효소처치를 하지 않은 것보다 효소처치를 한 경우 활성이 보다 높은 것으로 나타났으며, 곤드레의 함량이 증가함에 따라 항산화 및 면역활성이 유의하게 증가하는 경향을 나타났다.In the case of gondre, the enzyme treatment was higher than that without the enzyme treatment, and the antioxidative and immunological activity increased significantly as the gondre content increased.
본 연구의 결과로부터 마늘과 곤드레의 최적 공정은, 곤드레 효소처리물과 마늘 발효물의 혼합 공정인 것으로 확인되었다. From the results of this study, it was confirmed that the optimum process of garlic and gondre was a mixing process of gondre enzyme treatment and garlic fermented product.
한편, 곤드레는 원료의 단가가 매우 고가로서, 상기의 연구 결과를 고려하여 50%까지 혼합할 경우(S9) 경제성이 떨어지는 문제가 있고, 곤드레 발효물을 20%로 혼합한 시료(S8)의 경우 S9보다 항산화 및 면역활성이 크게 감소하지 않는 것으로 나타났다.On the other hand, Gondre has a problem that the unit price of the raw material is very expensive, and when considering up to 50% in consideration of the results of the above study (S9), the economy is inferior, and in the case of the sample (S8) in which the Gondry fermented product is mixed at 20% Antioxidant and immune activity was not significantly reduced than S9.
따라서, 원료의 생리활성 기능과 경제성을 고려하여, 본 연구의 마늘과 곤드레의 생물전환을 위한 최적 원료 혼합비는 마늘 80%와 곤드레 20%를 혼합하는 비율로 확정하였다.Therefore, considering the physiological activity and economic efficiency of the raw materials, the optimal mixing ratio of the raw materials for the bioconversion of garlic and gondre was determined as the ratio of 80% garlic and 20% gondle.
<실시예 2> (곤드레 마늘 발효물의 인비트로 기능성 평가)Example 2 (Invitro Functional Evaluation of Gondre Garlic Ferment)
1. 기능성 성분 분석1. Functional Ingredient Analysis
(1). DPPH 라디칼 소거능(One). DPPH radical scavenging activity
상기 실시예 1의 최적화된 공정을 적용하여 시생산한 곤드레 마늘 발효물 원료(FCG)의 항산화능을 평가하기 위하여, 상기 실시예 1과 같이 DPPH 라디칼 소거능을 측정한 결과를 도 6에 나타내었다.In order to evaluate the antioxidant capacity of the gondre garlic fermented raw material (FCG) produced by applying the optimized process of Example 1, the DPPH radical scavenging ability as shown in Example 1 is shown in FIG.
도 6에서 보는 바와 같이, 곤드레 마늘 발효물의 DPPH 라디칼 소거능을 측정한 결과, 원료를 0.1, 0.5, 1 mg/mL로 세포에 처리하였을 때 농도 의존적으로 DPPH 라디칼 소거능이 증가하였다. As shown in FIG. 6, DPPH radical scavenging ability of the Gondre garlic fermentation was measured. When the raw materials were treated with cells at 0.1, 0.5, and 1 mg / mL, DPPH radical scavenging ability increased in a concentration-dependent manner.
또한, 500 μg/mL의 농도로 처리하였을 때, 10 μg/mL 농도의 L-ascorbic acid(AsA)에 상응하는 DPPH 라디칼 소거능을 나타내었다.In addition, when treated at a concentration of 500 μg / mL, it showed DPPH radical scavenging ability corresponding to L-ascorbic acid (AsA) at a concentration of 10 μg / mL.
(2). FRAP 분석(2). FRAP analysis
상기 실시예 1과 같이 곤드레 마늘 발효물의 FRAP 활성을 분석한 결과를 도 7에 나타내었다. As shown in Example 1, the results of analyzing the FRAP activity of the gondre garlic fermentation are shown in FIG. 7.
도 7에서 보는 바와 같이, 로트(Lot) 혼합물을 농도별로 처리하였을 때 유의적으로 FRAP 활성이 증가하였고, 500μg/mL 농도로 처리한 경우 대조구 L-ascorbic acid(AsA) 10 μg/mL 보다 높은 FRAP 활성을 보였다. As shown in FIG. 7, the FRAP activity was significantly increased when the lot mixture was treated by concentration, and the FRAP higher than the control L-ascorbic acid (AsA) 10 μg / mL when treated with a concentration of 500 μg / mL. Showed activity.
2. 곤드레 마늘 발효물의 인비트로 면역 활성 평가2. In Vitro Immune Activity Evaluation of Gondre Garlic Ferment
(1). 세포독성(One). Cytotoxicity
선정된 원료가 적용된 곤드레 마늘 발효물(FCG)의 세포독성 여부를 확인하기 위해 XTT 어세이를 이용하여 세포 독성능을 측정한 결과를 도 8에 나타내었다. In order to confirm the cytotoxicity of the Gondre garlic fermented product (FCG) to which the selected raw material was applied, the results of measuring cytotoxicity using the XTT assay are shown in FIG. 8.
도 8에서 보는 바와 같이, 곤드레 마늘 발효물을 50, 100, 200 μg/mL 농도로 처리한 경우 모두 90% 이상의 세포 생존율을 나타내어, 세포독성에 큰 영향을 미치지 않는 것으로 나타났다.As shown in Figure 8, when treated with Gondre garlic fermentation at a concentration of 50, 100, 200 μg / mL all showed more than 90% cell viability, did not appear to have a significant effect on cytotoxicity.
(2). NO 생성능(2). NO generation ability
상기 실시예 1과 같은 방법으로 곤드레 마늘 발효물을 50, 100, 200 μg/mL 농도로 처리한 결과를 도 9에 나타내었다.In the same manner as in Example 1, the result of treating Gondre garlic fermented products at 50, 100, and 200 μg / mL concentrations is shown in FIG. 9.
도 9에서 보는 바와 같이, 곤드레 마늘 발효물의 경우 4.83, 4.71, 5.14 μM의 NO를 생성하여, 비처리군과 비교하였을 때 유의적으로 높은 NO를 생성하였다.As shown in FIG. 9, the Gondre garlic ferment produced NO of 4.83, 4.71, and 5.14 μM, which produced significantly higher NO compared to the non-treated group.
(3). TNF-α 생성능(3). TNF-α producing ability
TNF-α는 활성화된 대식세포 또는 비장세포에서 분비되는 염증성 사이토카인(Cytokine)으로서, 인체에 침입한 병원체 및 종양세포들에 대한 제거 활성을 증진시키며, 림프구와 상호작용하여 림프구의 활성과 성장 등을 조절한다. TNF-α is an inflammatory cytokine secreted from activated macrophages or splenocytes. It enhances the elimination activity of pathogens and tumor cells that invade the human body, and interacts with lymphocytes to activate and grow lymphocytes. Adjust
따라서, 면역 증진 효과를 평가하기 위해 대식세포에 시험물질을 가하여 배양하면서 TNF-α생성에 미치는 영향을 관찰한 결과를 도 10에 나타내었다. Therefore, the results of observing the effect on TNF-α production while culturing by adding a test substance to macrophages to evaluate the immune enhancing effect is shown in Figure 10.
도 10에서 보는 바와 같이, 곤드레 마늘 발효물을 처리하여 배양한 세포 배양액의 TNF-α 생성이 모두 증가한 결과를 보였으며, 곤드레 마늘 발효물이 대식세포를 활성화시키고 TNF-α생성을 촉진하여, 면역력을 증진시키는데 효과적임을 확인하였다.As shown in Figure 10, the TNF-α production of the cell culture cultured by treatment with gondre garlic fermentation showed an increase in all, Gondre garlic fermentation activates macrophages and promotes TNF-α production, immunity It was found to be effective in promoting the
(4). 인터류킨(Interleukine) 생성능(4). Interleukine Generating Ability
IL-1β는 단핵 백혈구와 대식세포계 세포에 의해 생성되는 사이토카인으로 T 세포를 활성화시키고, T 세포에서 분비되는 IL-2와 같은 사이토카인의 활성을 증진시키는 등 사이토카인 네트워크에 중요한 역할을 한다. IL-1β is a cytokine produced by monocytes and macrophage cells and plays an important role in the cytokine network by activating T cells and enhancing the activity of cytokines such as IL-2 secreted from T cells.
또한, IL-10은 B 세포의 증식을 유도하여 lgM, lgG, lgA 항체의 생산을 증가시키며, T 세포에 대한 사이토카인 합성 억제 역할을 하는 등 생체 내에서 면역 억제 역할과 부분적으로 림프구의 성장 촉진의 역할을 동시에 수행한다.In addition, IL-10 induces proliferation of B cells, increases production of lgM, lgG, and lgA antibodies, and plays a role in immunosuppression and partially promotes lymphocyte growth in vivo. Simultaneously plays the role of.
따라서, 원료의 면역 증강 효과를 평가하기 위해 대식세포에 첨가하여 배양하여 IL-1β 및 IL-10 생성에 미치는 영향을 관찰한 결과를 도 11 및 도 12에 나타내었다.Therefore, the results of observing the effect on the production of IL-1β and IL-10 by culturing added to macrophages to evaluate the immune enhancing effect of the raw material is shown in Figure 11 and 12.
도 11에서 보는 바와 같이, 곤드레 마늘 발효물을 대식세포에 농도별로 처리 하였을 때, 대조군에 비해 유의적으로 높은 IL-1β 생성능을 보였다.As shown in Figure 11, when treated with Gondre garlic fermentation by concentration in macrophages, showed a significantly higher IL-1β production capacity than the control.
또한, 도 12에서 보는 바와 같이, IL-10 생성능 또한 비처리구보다 유의적으로 증가하여 면역 증강 효능이 있음을 확인하였다.In addition, as shown in Figure 12, IL-10 production ability was also significantly increased than the non-treated group was confirmed that there is an immune enhancing effect.
<실시예 3> (곤드레 마늘 발효물을 포함하는 건강음료의 제조) Example 3 (Preparation of Health Drink Containing Gondre Garlic Ferment)
주원료로는 마늘과 곤드레를 생물전환 공정을 통하여 생산한 마늘 곤드레 발효물(마늘:곤드레=80:20)을 주성분으로 하였으며, 부원료로는 다양한 식물유래 천연농축액을 단가, 맛, 향 및 원료의 이미지를 고려하여 배농축액, 사과농축액, 유자농축액 등 과일 종류와 오미자농축액, 생강농축액, 당귀농축액, 대추농축액, 감초농축액 등의 한방원료 들을 선정하였다.The main ingredients are garlic gondre fermented products (garlic: gondre = 80:20) produced through the bioconversion process, and the main ingredients are various plant-derived natural concentrates, including unit price, taste, flavor and image of raw materials. Fruit ingredients such as pear concentrate, apple concentrate, and citron concentrate were selected, and herbal ingredients such as schizandra concentrate, ginger concentrate, donkey concentrate, jujube concentrate, and licorice concentrate were selected.
1. 곤드레 마늘 발효물의 순수한 발효농축 컨셉1. Pure Fermentation Concentration Concept of Gondre Garlic Ferment
순수한 마늘과 곤드레 발효 농축액의 이미지를 부각시켜 관능을 위한 원료만을 최소한으로 사용하여 하기 표 2와 같은 레시피를 제조하였다(A 그룹). 하기 표 2에서, 원재료 이외의 성분은 정제수이다.By highlighting the image of pure garlic and gondry fermentation concentrate to prepare a recipe as shown in Table 2 using only the raw material for the sensuality (Group A). In Table 2 below, components other than the raw materials are purified water.
2. 과즙 타입의 상큼하고 맛있는 발효음료 컨셉2. Fresh and delicious fermented beverage concept of juice type
최근 젊은 층의 트랜드에 맞추어, 마늘이 주는 스테미너의 이미지와 젊은 층이 선호하는 과즙향과 맛을 가미하여, 무탄산 또는 탄산음료 타입의 에너지드링크 컨셉의 하기 표 3과 같은 레시피를 제조하였다(B 그룹). 하기 표 3에서, 원재료 이외의 성분은 정제수이다.Recently, according to the trend of young layer, adding the image of stamina given by garlic and the fruit juice and taste preferred by the young layer, a recipe as shown in Table 3 of the energy drink concept of non-carbonated or carbonated beverage type was prepared (B group). In Table 3 below, components other than the raw materials are purified water.
3. 한방 발효음료 컨셉3. Herbal Fermented Beverage Concept
한방 관능 컨셉의 제품은 다양한 계층에서 선호도가 높은 관능으로, 최근 액상 파우치 또는 스틱제품에서 시장이 크게 성장하는 추세로 마늘 곤드레 발효물을 한방 원료들과 혼합한 하기 표 4와 같은 레시피를 제조하였다(C 그룹). 하기 표 4에서, 원재료 이외의 성분은 정제수이다.The product of the herbal sensory concept is a highly preferred sensory in various layers, and recently prepared a recipe as shown in Table 4 in which garlic gondry fermented product is mixed with herbal ingredients as the market is rapidly growing in liquid pouch or stick products. C group). In Table 4 below, components other than the raw materials are purified water.
<실시예 4> (관능 평가)Example 4 (Sensory Evaluation)
1. 평가 방법1. Evaluation method
곤드레 마늘 발효물 및 부원료를 다양한 비율로 혼합하여 상기 실시예 3과 같이 제조한 곤드레 마늘 발효 음료 9종에 대해 훈련된 관능검사 패널 15명을 대상으로 관능 평가를 실시하였다.Sensory evaluation was conducted on 15 sensory test panel trained for the nine goren garlic fermented beverages prepared in Example 3 by mixing the gondry garlic fermented product and the subsidiary materials in various ratios.
시료는 세자리 숫자로 표시하였으며 각각의 시료를 시음한 후에는 입을 헹굴 수 있도록 상온의 물을 제공하였고, 평가는 7가지 평가항목 (전체적 느낌, 외관, 향, 맛, 입안느낌, 뒷맛, 만족도)으로 진행하였으며, 평가 척도는 7점 척도(1: 대단히 싫다, 7: 대단히 좋다)가 사용되었다.Samples were represented by three digit numbers, and after each sample was sampled, water at room temperature was provided to rinse the mouth. The evaluation was made with seven evaluation items (overall feeling, appearance, aroma, taste, mouth feel, aftertaste, and satisfaction). A seven-point scale (1: disliked, 7: very good) was used.
음료 9종의 관능적 특성, 기호도 검사 결과에 대해 시료 간의 유의적 차이를 검증하기 위해 분산분석(analysis of variance, ANOVA)을 수행하였으며, 그 결과에 따라 Duncan’s multiple range test를 수행하였다(α=0.05). 통계 분석에는 SPSS statics 17.0 (SPSS Inc., Chicago, IL, USA)을 사용하였다.The analysis of variance (ANOVA) was performed to verify the significant differences between the samples on the sensory characteristics and palatability test results of nine beverages. Duncan's multiple range test was performed according to the results (α = 0.05) . For statistical analysis, SPSS statics 17.0 (SPSS Inc., Chicago, IL, USA) was used.
2. 평가 결과2. Evaluation result
곤드레 마늘 발효 음료 9종은 컨셉별 세 그룹으로 나누어 기호도 분석 및 그룹별 순위를 확인하였다. Nine gondre garlic fermented beverages were divided into three groups according to the concept and the preference analysis and group ranking were confirmed.
원료 집중 컨셉인 A 그룹의 음료 3종의 종합 기호도 분석 결과를 하기 표 5에 나타내었는데, 전체 종합 기호, 종합 선호 및 만족도에서 A1이 A2, A3 보다 높은 것으로 평가되었다. The results of the analysis of the overall preference of three beverages of group A, which is the concentration of raw materials, are shown in Table 5 below.
세부 기호도 결과는 하기 표 6에 나타내었는데, 맛, 뒷맛에서 A1이 A2, A3 보다 좋은 것으로 평가되었고, 외관, 향, 입안 느낌에서는 시료 간 차이가 뚜렷하지 않은 것으로 확인되었다.Detailed preference results are shown in Table 6 below, A1 was evaluated as better than A2 and A3 in taste and aftertaste, and it was confirmed that the difference between samples was not apparent in appearance, aroma, and mouthfeel.
과일 첨가 컨셉인 B 그룹 음료 3종의 종합 기호도 분석 결과는 하기 표 7에 나타네었는데, 전체 종합 기호도 및 만족도 항목에서는 시료간 차이가 없었고, 종합 선호도에서는 B3이 B1, B2보다 높은 것으로 확인되었다. The results of the analysis of the comprehensive preference of three kinds of beverages of the Group B, which is the fruit addition concept, are shown in Table 7 below.
세부 기호도 결과는 하기 표 8에 나타내었는데, 외관, 향, 맛, 입안 느낌은 시료간 유의적인 차이가 없었고, 뒷맛 항목에서는 B3가 B1, B2보다 기호도가 높은 것으로 평가되었다.Detailed preference results are shown in Table 8 below, but there was no significant difference between the samples in appearance, aroma, taste, and mouth feeling, and in the aftertaste category, B3 was evaluated to have higher preference than B1 and B2.
한방 컨셉인 C 그룹 음료 3종의 종합 기호도 분석 결과는 하기 표 9에 나타내었는데, 전체 종합 기호도 및 종합 선호도에서 C2가 나머지 시료보다 높게 평가되었고, 만족도에서는 유의적인 차이가 없었다. 만족도 항목에서는 시료간 차이가 없었고, 종합 선호도에서는 B3이 B1, B2보다 높은 것으로 확인되었다. The results of comprehensive preference analysis of three kinds of herbal group C beverages are shown in Table 9 below. C2 was evaluated higher than the rest of the samples in overall overall preference and overall preference, and there was no significant difference in satisfaction. There was no difference between samples in the satisfaction category, and B3 was higher than B1 and B2 in overall preference.
세부 기호도 결과는 하기 표 10에 나타내었는데, 외관, 향, 입안 느낌, 뒷맛에서는 시료간 차이가 없었고, 맛 항목에서는 C2가 C1, C3보다 높은 것으로 평가되었다.Detailed preference results are shown in Table 10 below. There was no difference between samples in appearance, aroma, mouthfeel, and aftertaste, and C2 was evaluated to be higher than C1 and C3 in the taste category.
또한, 각 그룹별로 기호도가 높았던 A1, B3, C2의 만족도 및 종합 기호도를 하기 표 11에 나타내었는데, 종합 기호도와 종합 선호도에서 C2가 A1, B3보다 높은 것으로 평가되었고, 만족도에서는 시료간 유의적 차이가 없었다. In addition, the satisfaction and the comprehensive preference of A1, B3, and C2, which had high preference for each group, are shown in Table 11 below, and C2 was evaluated to be higher than A1, B3 in the overall preference and overall preference, and there was a significant difference between samples in satisfaction. There was no.
A1, B3, C2의 세부 기호도를 하기 표 12에 나타내었는데, 맛, 입안 느낌 항목에서 C2가 다른 시료보다 기호도가 높은 것으로 평가되었고, 외관, 향, 뒷맛 항목에서는 유의적 차이가 없었다.The detailed preference of A1, B3, and C2 is shown in Table 12 below. In taste, mouth feeling, C2 was evaluated to have higher preference than other samples, and there was no significant difference in appearance, aroma, and aftertaste.
3. 결론 및 고찰3. Conclusion and Discussion
곤드레 마늘 발효음료 9종의 관능평가를 진행한 결과, 각 그룹별로는 A1, B3, C2가 종합 선호도 및 기호도가 높은 것으로 확인되었으며, 3종류의 시료(A1, B3, C2)의 기호도를 비교한 결과, C2가 가장 관능적으로 선호도가 높은 것으로 확인되었다.As a result of sensory evaluation of nine Gondre garlic fermented beverages, A1, B3, and C2 were found to have high overall preference and preference in each group, and compared with the preference of three samples (A1, B3, C2). , C2 was found to be the most sensory preference.
<실시예 5> (곤드레 마늘 발효물을 포함하는 건강음료의 제조) Example 5 (Preparation of Healthy Drink Containing Gondre Garlic Ferment)
상기 실시예 1의 1-5에서 제조한 마늘 및 곤드레 발효물(마늘:곤드레=80:20) .......................... 1 gGarlic and gondry fermented product prepared in 1-5 of Example 1 (garlic: gondry = 80: 20) ......................... 1 g
비타민 C..............................15 gVitamin C ........................ 15 g
비타민 E (분말)......................100 gVitamin E (powder) ............ 100 g
젖산철 ...............................19.75 gIron lactate ............... 19.75 g
산화아연...............................3.5 gZinc Oxide ............... 3.5 g
니코틴산아미드.........................3.5 gNicotinamide ......... 3.5 g
비타민 A...............................0.2 gVitamin A ............................ 0.2 g
비타민 B1..............................0.25 gVitamin B1 ............ 0.25 g
비타민 B2 .............................0.3gVitamin B2 ............. 0.3g
물 ................................... 1 LWater ................................... 1 L
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 1시간 동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2 L 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관하여 건강음료 조성물을 제조하였다.After mixing the above components according to the conventional healthy beverage production method, and then stirred and heated at 85 ℃ for 1 hour, the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated stored in a healthy beverage composition Was prepared.
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요 계층, 수요 국가, 사용 용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is mixed with a component suitable for a favorite beverage in a preferred embodiment, the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and use purpose.
상술한 바와 같이 본 발명의 바람직한 실시예를 참조하여 설명하였지만, 본 발명의 기술 분야에서 통상의 지식을 가진 통상의 기술자라면 하기의 청구범위에 기재된 본 발명의 사상 및 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다. Although described with reference to the preferred embodiment of the present invention as described above, those skilled in the art without departing from the spirit and scope of the present invention described in the claims below It will be understood that various modifications and variations can be made to the invention.
본 발명에 의하면, 마늘과 곤드레의 블렌딩 및 유산균 발효를 이용하여 항산화 활성 및 면역 활성이 증진된 마늘과 곤드레 유산균 발효물을 제공할 수 있고, 상기의 유산균 발효물을 음료 등과 같은 건강기능 식품의 소재로 활용할 수 있는 장점이 있기 때문에, 본 발명이 속하는 기술분야에 유용하게 적용될 수 있다.According to the present invention, by using a blend of garlic and gondre and fermentation of lactic acid bacteria, it is possible to provide garlic and gondry lactobacillus fermented products having enhanced antioxidant and immune activity, and the lactic acid bacteria fermented products of the health functional food such as beverages Since there is an advantage that can be utilized, it can be usefully applied to the technical field to which the present invention belongs.
Claims (14)
(b). 상기 혼합된 마늘 추출물 및 곤드레 효소처리 추출물의 혼합물에 유산
균을 접종하고, 발효시키는 단계를 포함하는, 마늘 및 곤드레 유산균 발효물의 제조방법. (a). Mixing garlic extract and gondre enzyme treatment extract; And
(b). Lactic acid in the mixture of the mixed garlic extract and gondre enzyme treatment extract
Inoculating bacteria and fermentation, comprising the step of fermenting garlic and gondre lactic acid bacteria.
상기 여과한 추출물을 8~12 브릭스로 농축시킨 후, 40~55℃에서 5~8시간 동안 비스코자임(viscozyme)을 처리하는 단계를 포함하여 제조되는 것을 특징으로 하는 마늘 및 곤드레 유산균 발효물의 제조방법. The method according to claim 5, wherein the gondre enzyme treatment extract, after immersing the dried gondre in water by 5 to 15 times by weight ratio, extracting for 3 to 5 hours by applying 80 ~ 100 ℃ heat and then filtering; And
Concentrating the filtered extract to 8 to 12 Brix, garlic and gondre lactobacillus production method characterized in that it comprises the step of treating biscozyme (viscozyme) for 5-8 hours at 40 ~ 55 ℃ .
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180060890 | 2018-05-29 | ||
KR20180060890 | 2018-05-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190135902A true KR20190135902A (en) | 2019-12-09 |
KR102149139B1 KR102149139B1 (en) | 2020-08-28 |
Family
ID=68837601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180126805A KR102149139B1 (en) | 2018-05-29 | 2018-10-23 | Fermented product of garlic and Cirsium setidens nakai by lactic acid bacteria, method of manufacturing the same, and use of the same |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102149139B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230053030A (en) * | 2021-10-13 | 2023-04-21 | 농업회사법인 유한회사 아리울현푸드 | Kimchi seasoning sauce using enzyme and Kimchi using the same |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6146638A (en) * | 1996-12-10 | 2000-11-14 | Wakunaga Pharmaceutical Co., Ltd. | Fermented garlic composition |
KR20080096307A (en) * | 2007-04-27 | 2008-10-30 | 주식회사 유엔아이 | Black garlic fermented by natural herb, processes for the preparation thereof, and health food comprising the same |
KR20090053352A (en) * | 2007-11-23 | 2009-05-27 | 재단법인 대구테크노파크 | A beverage containing onion concentrate and a method for preparing the same |
US20100159039A1 (en) * | 2008-12-09 | 2010-06-24 | Liisna Inc. | Antiviral agents containing a fermentation product of garlic by lactic acid bacteria |
KR20110125930A (en) * | 2010-05-14 | 2011-11-22 | 주식회사 웰빙엘에스 | Fermented black garlic using vegetable lactic acid bacteria with yeast extract and mineral and a method thereof |
KR20120071858A (en) * | 2010-12-23 | 2012-07-03 | 박선희 | Fermented extract of garlic and manufacturing process of the same |
KR20130058520A (en) * | 2011-11-25 | 2013-06-04 | 재단법인 경북바이오산업연구원 | Functional fermented allium victorialis l. and manufacturing method thereof |
US20170119839A1 (en) * | 2014-04-22 | 2017-05-04 | Hyun Soo CHUN | Method for preparing garlic-fermented composition and garlic-fermented composition prepared by same method |
KR20170058075A (en) * | 2015-11-18 | 2017-05-26 | 강원대학교산학협력단 | Antidiabetic composition containing of cirsium setidens nakai extract method of preparing the same |
-
2018
- 2018-10-23 KR KR1020180126805A patent/KR102149139B1/en active IP Right Grant
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6146638A (en) * | 1996-12-10 | 2000-11-14 | Wakunaga Pharmaceutical Co., Ltd. | Fermented garlic composition |
KR20080096307A (en) * | 2007-04-27 | 2008-10-30 | 주식회사 유엔아이 | Black garlic fermented by natural herb, processes for the preparation thereof, and health food comprising the same |
KR20090053352A (en) * | 2007-11-23 | 2009-05-27 | 재단법인 대구테크노파크 | A beverage containing onion concentrate and a method for preparing the same |
US20100159039A1 (en) * | 2008-12-09 | 2010-06-24 | Liisna Inc. | Antiviral agents containing a fermentation product of garlic by lactic acid bacteria |
KR20110125930A (en) * | 2010-05-14 | 2011-11-22 | 주식회사 웰빙엘에스 | Fermented black garlic using vegetable lactic acid bacteria with yeast extract and mineral and a method thereof |
KR20120071858A (en) * | 2010-12-23 | 2012-07-03 | 박선희 | Fermented extract of garlic and manufacturing process of the same |
KR20130058520A (en) * | 2011-11-25 | 2013-06-04 | 재단법인 경북바이오산업연구원 | Functional fermented allium victorialis l. and manufacturing method thereof |
US20170119839A1 (en) * | 2014-04-22 | 2017-05-04 | Hyun Soo CHUN | Method for preparing garlic-fermented composition and garlic-fermented composition prepared by same method |
KR20170058075A (en) * | 2015-11-18 | 2017-05-26 | 강원대학교산학협력단 | Antidiabetic composition containing of cirsium setidens nakai extract method of preparing the same |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230053030A (en) * | 2021-10-13 | 2023-04-21 | 농업회사법인 유한회사 아리울현푸드 | Kimchi seasoning sauce using enzyme and Kimchi using the same |
Also Published As
Publication number | Publication date |
---|---|
KR102149139B1 (en) | 2020-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109717340B (en) | Fermentation preparation method of two-step cordyceps militaris enzyme combined with composite enzymolysis | |
JP4163631B2 (en) | Fermentation composition of spicy varieties of chili pepper and its use | |
KR101467837B1 (en) | Manufacturing method of fermented red ginseng extract with enhanced ginsenosides Rg3 and antioxidant activity | |
KR102214532B1 (en) | health food composition using pomegranate fermented by lactic acid bacteria and manufacturing method thereof | |
CN103125941A (en) | Chinese magnoliavine fruit leavening product, Chinese magnoliavine fruit and ginseng leavening product and application thereof | |
KR20180069198A (en) | A moisturizing and anti-wrinkle cosmetic composition comprising fermented barley, fermented pear juice, fermented soybeans and fermented pomegranate extract and the method preparation of thereof | |
KR101091833B1 (en) | Methods for preparing high quantity of S-allyl-L-cysteine to fermented products of garlic using lactic acid bacteria | |
KR20220067980A (en) | Composition for antioxidant and immunity improvement activity containing natural extracts and health functional food containing the same | |
KR102105316B1 (en) | Process for producing functional beverage using mixed fermented extract of Inonotus Obliquus, Phellinus linteus and Ganoderma lucidum fermented with probiotic Lactobacillus and functional drinks thereof | |
KR20220136107A (en) | Method for producing fermented product by lactic acid bacteria of Aloe with increased effective component content and postbioics products containing the same | |
KR20190002036A (en) | Prebiotics comprising blueberry extract for proliferating intestinal probiotics the use thereof | |
Li et al. | Investigation on the nutrient and quality features of jujube juice fermented by selected Lactobacillus acidophilus 6074 | |
KR102149139B1 (en) | Fermented product of garlic and Cirsium setidens nakai by lactic acid bacteria, method of manufacturing the same, and use of the same | |
KR20160126591A (en) | Method of producing ginseng fermented extract, Ginseng fermented extract produced by the same and Health functional foods comprising the same | |
JP2005058133A (en) | Method for producing extract or fermented product having high palatability | |
CN108703289B (en) | Probiotic beverage prepared from spirulina and sea buckthorn juice and preparation method thereof | |
KR101682916B1 (en) | Composition comprising steamed and fermented Lycium chinense extract with increased anti-inflammatory or antioxidant activity and preparation method thereof | |
JP2006075083A (en) | Fermented product obtained from balsam pear | |
KR102303125B1 (en) | Method for producing double-coating red ginseng granule with enhanced ginsenoside content and improved preservability | |
KR101368634B1 (en) | Health functional food comprising Ginseng cultivates fermentation and method for manufacturing thereof | |
KR20190072923A (en) | Antioxidant and Immune-enhancing functional beverage and food composition comprising the extract of edible flowers fermented by lactic acid bacteria and preparation method of the same | |
KR20230080923A (en) | Method for producing a ferment extract of the centella asiatica and composition for antiocidative comprising the ferment extract of the centella asiatica produced by the same | |
KR20140039742A (en) | New microorganism lactobacillus panaxicasei for fermentation of red ginseng and food composition containing fermented red ginseng produced using the same | |
KR101768817B1 (en) | Food composition for anti-oxidation and inhanced immunity comprising chamomile flower extract short-term fermented by lactic acid bacteria and the method of preparation thereof | |
Adebo et al. | Fermented beverages from Opuntia species: composition, commercialization and future outlook |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |